Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicriviroc compassionate-use treatment protocol in HIV-infected subjects (substudy of P03802)
2005-001843-49Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vicriviroc in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoint: Long-term safety and tolerability of vicriviroc. Started Aug 2005; status: terminated.
02
Drugs
vicriviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2005-001843-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001843-49.